Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'. - Wikidata - awgldk - TriplyDB

Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'.

Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'.

http://www.wikidata.org/entity/Q38390560

about

Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.Optimizing the virological success of tenofovir DF/FTC/rilpivirine in HIV-infected naive and virologically suppressed patients through strict clinical and virological selection.Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.Simultaneous determination and validation of emtricitabine, rilpivirine and tenofovir from biological samples using LC and CE methods.Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.

P2860

Q28546894-0E2CD850-85E7-45F5-8539-447CEAF3552B Q36146704-2000EDA1-EB67-4855-A427-C7B4D5ED1729 Q38379391-DB151EBA-5AE4-406A-A9D8-02423A0CA78A Q39980493-0B671E3A-1972-4D1D-BA05-31EE319DD015 Q40116904-C381B163-E7D8-47CD-86E2-44186E9BA274 Q47568259-3E3E07FF-388E-4F51-A412-3138D3995E85 Q49925457-782B4678-2BB8-4DA4-982B-B992DE5AF48E

P2860

Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'.

http://www.wikidata.org/entity/Q38390560

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Initiation of rilpivirine, ten ...... nce assessment in 'real life'.

@en

type

label

Initiation of rilpivirine, ten ...... nce assessment in 'real life'.

@en

prefLabel

Initiation of rilpivirine, ten ...... nce assessment in 'real life'.

@en

P1433

Q38390560-E4D352AC-C476-483C-8167-E1211401ED8C

P1476

Q38390560-0B33F44C-BA42-4625-AD22-4F04CCCD54F2

P2093

Q38390560-11368A15-DB21-4A31-A93A-067D8F5A977A

Q38390560-2F93C7E6-CAE6-4E31-9991-0F49D1FECD2A

Q38390560-58701670-78EA-4FB4-BDA3-D9B0CE8DBA58

Q38390560-6F4DD750-C764-498F-A32E-60B4395B1566

Q38390560-7FE9B900-6F61-4361-AEE3-D820F51721FA

Q38390560-82DB4BA0-420D-48BF-896A-ACC7E4E24216

Q38390560-BDA042DF-2EB1-4B20-91A4-9B204136934C

Q38390560-DEB83BA5-AE38-4172-9B46-41642722EBF4

Q38390560-EBD71A8F-4952-442C-9B4C-9456CDA55BF7

P2860

Q38390560-1FA1211A-9632-4C70-831B-A40F46A0FF44

Q38390560-24E2ABC2-B5BE-4D88-9DD9-F2B49C5312D0

Q38390560-318A9A5E-96F2-4DDD-B1EC-598B529DE787

Q38390560-8941718C-1D65-44C9-876D-1CE966391B51

Q38390560-9346CE2D-EBB7-4FB9-A168-2B25E0CA81C9

P304

Q38390560-98BD32E9-1B99-4638-9C4E-E09671CBDBDB

P31

Q38390560-4EC4DF1E-D2BD-4473-BEB9-FEBADE2F41A3

P356

Q38390560-604CD1B3-043D-410D-BBDD-22EA84F8D62C

P407

Q38390560-0DFB14B6-F3EC-4A43-B7F4-156D1E8F7904

P433

Q38390560-7AA467AC-7294-4F28-BA73-5460F6C4794E

P478

Q38390560-94883D06-790F-4CCA-A5A5-8006EC01D908

P577

Q38390560-67723485-000F-45E3-B8C6-5D0295014F24

P698

Q38390560-DB8FAD42-7D4A-427D-9E6D-90011BB5F647

P921

Q38390560-43B0A9FB-2632-4E18-912D-60492554A32F

P356

P1433

Journal of Antimicrobial Chemotherapy

P1476

Initiation of rilpivirine, ten ...... nce assessment in 'real life'.

@en

P2093

Catherine Lependeven

http://www.w3.org/2001/XMLSchema#string

Corinne Amiel

http://www.w3.org/2001/XMLSchema#string

Gilles Pialoux

http://www.w3.org/2001/XMLSchema#string

Julie Chas

http://www.w3.org/2001/XMLSchema#string

Khadijah Kherallah

http://www.w3.org/2001/XMLSchema#string

Marie-Gisele Lebrette

http://www.w3.org/2001/XMLSchema#string

Mohammed Hamidi

http://www.w3.org/2001/XMLSchema#string

Sabine Guessant

http://www.w3.org/2001/XMLSchema#string

Veronique Schneider

http://www.w3.org/2001/XMLSchema#string

P2860

Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.

Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.

96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.

HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach.

P304

3335-3339

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKU294

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25114163

http://www.w3.org/2001/XMLSchema#string

P921